Coherus Oncology, Inc.
CHRS
$1.13
-$0.04-3.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 34.94% | -85.97% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 34.94% | -85.97% | |||
| Cost of Revenue | 27.97% | -92.16% | |||
| Gross Profit | 38.68% | -75.62% | |||
| SG&A Expenses | 0.05% | -24.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.10% | -40.87% | |||
| Operating Income | -0.11% | -27.82% | |||
| Income Before Tax | 5.35% | 6.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.35% | 6.51% | |||
| Earnings from Discontinued Operations | 3,836.00% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 626.38% | -11.58% | |||
| EBIT | -0.11% | -27.82% | |||
| EBITDA | -0.18% | -28.62% | |||
| EPS Basic | 625.33% | -11.18% | |||
| Normalized Basic EPS | 5.51% | 78.59% | |||
| EPS Diluted | 625.33% | -4.20% | |||
| Normalized Diluted EPS | 5.51% | 78.59% | |||
| Average Basic Shares Outstanding | 0.19% | 0.38% | |||
| Average Diluted Shares Outstanding | 0.19% | 0.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||